Researchers conducted a systematic review of the literature investigating the associations between lifestyle, health behaviors, and health outcomes.
Risk adjusted net present value: What is the current valuation of Pfizer’s PF-07275315?
PF-07275315 is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Atopic Dermatitis (Atopic Eczema).